Alzheimer’s patent dismissed

Information provided on a class of antibodies for treatment of Alzheimer’s disease and related disorders involving amyloid plaques in the brain, was judged insufficient to make it plausible for a patent. In addition clinical trials conducted after the patent filing date showed the invention was not effective for the claimed use.

Leave a comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s